BMS-986278 + nintedanib

BMS-986278 + nintedanib is a combination therapy being investigated for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF, also called PF-ILD). BMS-986278 (also known as admilparant) is an oral, selective lysophosphatidic acid receptor 1 (LPA1) antagonist that reduces fibroblast recruitment and inhibits fibrotic processes implicated in pulmonary fibrosis[4][6][9]. Nintedanib is a small molecule tyrosine kinase inhibitor that targets multiple receptors (including platelet-derived growth factor receptors, fibroblast growth factor receptors, and vascular endothelial growth factor receptors), thus acting as an antifibrotic by inhibiting key pathways in the progression of fibrotic lung disease[5]. Clinical trials for BMS-986278 were designed to allow stable background therapy with nintedanib, and subgroup analyses have included patients receiving this combination[1][3][4]. The combination is intended to provide additive or synergistic antifibrotic effects in IPF or PF-ILD.

Brand names

VargatefOfev

Other names

BMS-986278 + nintedanib